Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT02482454
Active, not recruiting Phase 2/3

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

NCT02482454 · tracked via the Priya Life Science China tracker
Sponsor
The First People's Hospital of Changzhou
Phase
Phase 2/3
Started
2012-07
Last updated
2017-08-01

Condition(s) studied

Cholangiocarcinoma

Investigational drug(s) / intervention(s)

Radiofrequency ablationCytokine-induced killer cells

Radiofrequency ablation: Radiofrequency ablation is performed percutaneously under CT/US guidance

Cytokine-induced killer cells: The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Study summary

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.

Eligibility

Sex
ALL
Min age
30 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with histologically confirmed cholangiocarcinoma * Primary lesions (cholangiocarcinoma) are not resected * Serum bilirubin level of 2.0 mg/dl or less. * Performance status of 0 or 1. * Expected survival of 1 year or more. * Informed consent from the patient. Exclusion Criteria: * With extrahepatic metastases * With other neoplastic disease that is measurable or being treated other than cholangiocarcinoma.

Primary outcome measure(s)

  • Recurrence-free survival — 1 year
    Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.

Trial sites (1)

FacilityCityRegionStatus
The First People's Hospital of Changzhou Changzhou Jiangsu

More The First People's Hospital of Changzhou trials in China

Clinical Trial of Safety and Efficacy of Intracranial Laser Balloon Dilation Catheter in Patients With Symptomatic Intracranial Atherosclerotic Stenosis: A Prospective, Multi-center, Randomized Comparison Enrolling by invitation
Human Umbilical Cord Mesenchymal Stem Cell Infusion for Type 2 Diabetic Nephropathy Starting soon
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis Recruiting
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC Recruiting

Other trials for the same condition

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer Recruiting
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study Starting soon
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer Starting soon
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma Recruiting
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02482454 on ClinicalTrials.gov ↗ ← All trials in China